Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials by Goldstein, J L et al.
Haemoglobin decreases in NSAID users over time: an analysis
of two large outcome trials
J. L. Goldstein*, F. K. L. Chan
, A. Lanas
, C. M. Wilcox
§, D. Peura
–, G. H. Sands**, M. F. Berger**, H. Nguyen** &
J. M. Scheiman

*Department of Medicine, University
of Illinois at Chicago, Chicago, IL,
USA.
Department of Medicine and
Therapeutics, Prince of Wales
Hospital, Shatin, Hong Kong.
University of Zaragoza, Aragon
Health Research Institute
(IIS Arago ´n) CIBERehd, Spain.
§Division of Gastroenterology/Hepa-
tology, University of Alabama at Bir-
mingham, Birmingham, AL, USA.
–Division of Gastroenterology and
Hepatology, University of Virginia
Health Sciences Center,
Charlottesville, VA, USA.
**Pﬁzer Inc, New York, NY, USA.
Division of Gastroenterology,
Department of Internal Medicine,
University of Michigan Medical
School, Ann Arbor, MI, USA.
Correspondence to:
Dr J. L. Goldstein, Department of
Medicine, University of Illinois at
Chicago, 840 South Wood Street
(m⁄c787), Room 1020 - 10th Floor,
Chicago, IL 60612, USA.
E-mail: jlgoldst@uic.edu
Publication data
Submitted 4 March 2011
First decision 26 March 2011
Resubmitted 4 July 2011
Accepted 5 July 2011
EV Pub Online 2 August 2011
Re-use of this article is permitted in
accordance with the Terms and
Conditions set out at http://
wileyonlinelibrary.com/onlineopen#
OnlineOpen_Terms
SUMMARY
Background
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) have been associated with
clinically signiﬁcant decreases in haemoglobin dependent and independent
of acute bleeding events.
Aim
To evaluate the incidence and time to a clinically meaningful decrease in
haemoglobin in two double-blind, prospective randomised clinical trials
comparing NSAIDs in patients with osteoarthritis (OA) or rheumatoid
arthritis (RA).
Methods
In CLASS, patients with OA⁄RA who were aged ‡18 years and required
continuous NSAID treatment were included; patients who were Helicobacter
pylori positive and⁄or using aspirin were not excluded. In contrast, in the
CONDOR trial, comparing celecoxib alone to diclofenac sustained release
(plus omeprazole), patients were aged ‡60 years or ‡18 years with a history
of gastroduodenal ulcer and were H. pylori negative; aspirin or other anti-
platelet users were excluded. To make a parallel post hoc analysis we limited
our study to 6 months and the populations to only the non-aspirin users in
CLASS and those patients receiving either celecoxib or diclofenac.
A decrease in haemoglobin of ‡2g⁄dL deﬁned the primary end point.
Results
At 6 months, in the CLASS and CONDOR trials, 1.9% and 2.0% of patients
treated with celecoxib and 3.3% and 5.7% of patients treated with diclofe-
nac developed a ‡2g⁄dL decrease in haemoglobin, respectively, [CLASS:
odds ratio (OR) 1.80 (95% conﬁdence interval (CI), 1.22–2.65) and CON-
DOR: OR 2.93 (95% CI, 2.06–4.15), respectively].
Conclusion
In these two large, independent trials, clinically-meaningful decreases in
haemoglobin ‡2g⁄dL occurred in a relatively similar fashion over time
despite differences in trial designs.
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Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
among the most widely prescribed class of drugs world-
wide
1 because of their anti-inﬂammatory, anti-pyretic
and analgesic properties. However, despite their well-
accepted efﬁcacy, chronic use of NSAIDs is associated
with an increased risk of gastrointestinal (GI) mucosal
injury and overt bleeding events.
2, 3
Previous prospective, randomised outcome studies have
focused primarily on GI events in the upper GI tract
4–9
but recent evidence has shown that injury to the small
bowel and colon during chronic NSAID use can lead to
mucosal damage, ulceration, overt bleeding, obstruc-
tion⁄perforation, protein-loss and occult blood loss (with
an associated decrease in haemoglobin).
2, 10–15 Extending
the understanding of small bowel and colonic injury asso-
ciated with NSAID use, the Celecoxib vs Omeprazole and
Diclofenac for At-risk Osteoarthritis (OA) and Rheuma-
toid Arthritis (RA) Patients (CONDOR) trial was a
prospective randomised outcome trial of 6 months dura-
tion that utilised a novel comprehensive composite pri-
mary end point of both upper and lower GI events,
including clinically signiﬁcant decreases in haemoglobin
(‡2g⁄dL).
16, 17 In CONDOR the authors reported that
the risk of the adjudicated composite primary end point
for clinically signiﬁcant outcomes throughout the GI tract
was lower in patients treated with a cyclo-oxygenase
(COX)-2-selective NSAID than in those receiving a nonse-
lective NSAID plus a proton pump inhibitor (PPI). Nota-
bly, the difference between the two treatment arms for the
primary end point of this trial appeared to be driven by
one of the components of the composite end point, the
number of patients reaching the predeﬁned cut-off point
for a decrease in haemoglobin (‡2g⁄dL) and⁄or haemato-
crit (‡10%) over the time of exposure to drug.
Like the CONDOR trial, the Celecoxib Long-Term
Arthritis Safety Study (CLASS)
8 was a large prospective
randomised, double-blind trial with patients followed for
up to 15 months evaluating GI outcomes using celecoxib
and nonselective NSAIDs for the treatment of patients
with arthritis. As haemoglobin values were collected
sequentially over time in both trials, we identiﬁed an
opportunity to evaluate changes in haemoglobin values
in these two independent trials. We hypothesised that
the pattern of haemoglobin decreases (presumably asso-
ciated with chronic gross or occult blood loss) may be
similar between the trials. Thus, in these two studies and
in a non-aspirin using population, we evaluated and
compared the incidence and time to event for a mean-
ingful end point deﬁned by a decrease in haemoglobin of
‡2g⁄dL
18 after 6 months. To ensure the focus of our
results would better reﬂect clinical practice we also anal-
ysed patients in whom the ‡2g⁄dL decrease in haemo-
globin led to laboratory-deﬁned anaemia (deﬁned as a
haemoglobin level £11.5 g⁄dL).
MATERIALS AND METHODS
Study designs
The CLASS trial was a double-blind, prospective, rando-
mised clinical trial conducted in patients with OA and
RA in North America. Patients were enrolled based on
the judgement of the local principal investigator regard-
less of the patients’ baseline GI risk for an NSAID-associ-
ated complication. A total of 8059 patients were enrolled
and 7968 randomised in a 2:1:1 ratio to receive oral celec-
oxib 400 mg b.d. (Pﬁzer Inc, New York, NY, USA), ibu-
profen 800 mg t.d.s. (G.D. Searle & Co., Skokie, IL, USA),
or diclofenac 75 mg b.d. (G.D. Searle & Co.) for up to
15 months (Figure 1a). Aspirin use for cardiovascular
(CV) prophylaxis was allowed (£325 mg⁄day) in this trial.
The primary end point was the incidence of predeﬁned
adjudicated upper GI events as previously reported.
8 In
comparison, the CONDOR trial (NCT00141102) was a
double-blind, triple-dummy, randomised, parallel-group,
multicentre, international study comparing treatment
with celecoxib (Pﬁzer Inc) alone versus diclofenac sus-
tained release (SR) (Novartis Pharmaceuticals UK, Cam-
berley, Surrey, UK) plus omeprazole (AstraZeneca LP,
Wilmington, DE, USA) in patients with OA and⁄or RA
at increased risk of GI adverse events. A total of 4484
patients were enrolled and randomised in a 1:1 ratio to
receive either oral celecoxib 200 mg b.d. or diclofenac SR
75 mg b.d. plus omeprazole 20 mg o.d. for 6 months
(Figure 1b). No aspirin use was allowed in this trial. The
primary end point was the incidence of a predeﬁned
comprehensive composite primary end point of both
upper and lower GI events, including clinically signiﬁcant
decreases in haemoglobin (‡2g⁄dL) and⁄or haematocrit
(‡10%), as previously reported.
16, 17
Study population
In the CLASS trial male or female patients aged ‡18 years
were eligible for inclusion if they had been diagnosed
with OA⁄RA for at least 3 months and were expected to
require continuous treatment with an NSAID for the
duration of the trial; patients who were Helicobacter
pylori positive and⁄or using aspirin were not excluded
from this trial. In the CONDOR trial, male or female
patients with OA⁄RA who were expected to require daily
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the management of their arthritis symptoms and who
had increased GI risk were eligible for inclusion. For the
CONDOR trial, increased GI risk was deﬁned as those
patients aged ‡60 years or ‡18 years who had gastroduo-
denal (GD) ulceration 90 days or more prior to screening.
In contrast to CLASS, patients who were H. pylori posi-
tive or using aspirin⁄other anti-platelet agents were
excluded from the CONDOR trial. To make a parallel
analysis in both trials, patients in the CLASS trial who
were receiving aspirin (n = 882 and n = 445 in the celec-
oxib and diclofenac groups, respectively) were excluded
from this analysis. Furthermore, since only diclofenac
(SR) was used in CONDOR as the nonselective NSAID
whereas diclofenac and ibuprofen were used in CLASS,
we only evaluated the pattern of clinically signiﬁcant
decreases in haemoglobin ‡2g⁄dL with diclofenac vs. cel-
ecoxib (Table 1). While we are comparing diclofenac
arms in the two trials it should be noted that the formu-
lations of diclofenac differed, as shown in Table 1. Fur-
thermore, a substantial difference between these trials
that may have affected this analysis was the required use
of PPIs in the CONDOR trial which was not allowed in
the CLASS trial. For this analysis we made the assump-
tion that injury beyond the upper GI tract would not be
inﬂuenced by the administration of a PPI.
Figure 1 | Study designs for the
(a) CLASS and (b) CONDOR
trials.
Table 1 | Comparison of the CLASS and CONDOR trials
CLASS CONDOR
Similarities
OA or RA
Anticipated regular use of NSAID therapy for at least 6 months
Use of NSAIDs, anti-ulcer drugs, sucralfate, misoprostol excluded
Differences
Up to 15 months duration 6 months duration
Age ‡18 years Increased GI risk (age ‡60 years or ‡18 years with history of GD ulcer)
H. pylori negative or positive H. pylori negative
Aspirin (£325 mg) use allowed No aspirin use
Celecoxib 400 mg b.d. Celecoxib 200 mg b.d.
Diclofenac, ibuprofen; PPI use was not allowed Diclofenac SR plus PPI (omeprazole)
OA, osteoarthritis; RA, rheumatoid arthritis; NSAID, nonsteroidal anti-inﬂammatory drug; PPI, proton pump inhibitor.
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For both trials, a decrease in haemoglobin of ‡2g⁄dL
was used to deﬁne the clinically meaningful end point as
previously described by us and others.
16–18 In addition, a
post hoc analysis was performed for patients who had a
decrease in haemoglobin ‡2g⁄dL that resulted in labora-
tory-deﬁned anaemia (haemoglobin level £11.5 g⁄dL).
While the CLASS trial followed patients for up to
15 months, for purposes of this analysis, we chose the 6-
month time frame to allow us to make parallel compari-
sons between the two studies.
Statistical analysis
The proportions of patients in the CLASS and CONDOR
trials with a haemoglobin drop of ‡2g⁄dL were estimated
using the laboratory data collected at scheduled and
unscheduled visits; odds ratio and conﬁdence intervals (CI)
have also been presented. The time to haemoglobin drop of
‡2g⁄dL was analysed using a log-rank test and summar-
ised using Kaplan–Meier curves; the proportion of patients
with haemoglobin drops of ‡2g⁄dL by day 180 (6 months)
were also estimated from the Kaplan–Meier curve.
RESULTS
Patient populations and demographics
Overall 1845 and 1730 non-aspirin users receiving celec-
oxib and 890 and 1621 non-aspirin users receiving
diclofenac completed the CLASS and CONDOR trials,
respectively (Figure 2). In CLASS, 41.3% of patients
withdrew from the trial in the celecoxib and diclofenac
arms by 6 months for reasons including treatment fail-
ure, protocol violation, noncompliance, laboratory abnor-
malities, adverse events and death (Table S1); in
CONDOR, 25.3% withdrew for similar reasons
(Table S2).
16
For the purposes of this analysis, only the baseline
demographics for those patients who were non-aspirin
users in the CLASS trial are displayed (Table 2). The
baseline demographics for the complete total population
in CLASS have previously been reported by Silverstein
et al.
8
There were more women and more patients with OA
or a previous history of GD ulcers in the CONDOR trial
than in CLASS, while more patients in the CLASS trial
were white. Although patients with H. pylori infection at
baseline were excluded from the CONDOR trial
(patients had to test negative for H. pylori at the screen-
ing visit or to have conﬁrmed eradication of the infec-
tion at a re-screening visit to be included), they were
included in the CLASS trial; the patient population used
in this secondary analysis included participants regard-
less of their H. pylori status. In the CLASS trial 38.2%
and 37.3% of patients were H. pylori positive in the cel-
ecoxib and diclofenac treatment arms respectively
(Table 2).
Figure 2 | Study disposition
(non-aspirin users in the
CLASS and CONDOR trials).
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decrease in haemoglobin during 6 months
In the non-aspirin using population of the CLASS and
CONDOR trials, 1.9% and 2.0% of patients treated
with celecoxib developed a ‡2g⁄dL decrease in hae-
moglobin during 6 months of treatment, respectively.
In contrast, a greater percentage of patients receiving
diclofenac developed a ‡2g⁄dL decrease in haemoglo-
bin by 6 months; 3.3% in CLASS and 5.7% in CON-
DOR, respectively. The corresponding odds ratio for
CLASS and CONDOR were both signiﬁcant at
6 months [CLASS: 1.80 (95% CI, 1.22–2.65) and CON-
DOR: 2.93 (95% CI, 2.06–4.15), respectively]. As seen
in Figure 3a for CLASS and 3b for CONDOR, the
time to a decrease in haemoglobin ‡2g⁄dL occurs at
a slower rate in the celecoxib arm than in the diclofe-
nac arm (log-rank test P < 0.01). Furthermore, based
on these Kaplan–Meier curves (Figure 3a,b), the esti-
mates of the proportion of patients with a decrease in
haemoglobin ‡2g⁄dL were 1.8% and 3.4% in CLASS
and 2.2% and 5.7% in CONDOR for the celecoxib and
diclofenac arms, respectively. Despite differences in the
methodology for calculating these rates (incidence vs.
Kaplan–Meier analysis), the rates reported above are
consistent with the Kaplan–Meier curves in Fig-
ure 3a,b.
Aspirin users crude rate
In the CLASS trial, a sub-population of aspirin users
(£325 mg per day of aspirin) was identiﬁed.
8 As seen in
Table 3, at 6 months there was a greater percentage of
subjects with a decrease in haemoglobin ‡2g⁄dL in
those using aspirin plus diclofenac as compared to those
receiving aspirin plus celecoxib with a corresponding
odds ratio of 1.71 (95% CI, 1.00–2.92).
CLASS and CONDOR: Patients meeting a ‡2g⁄dL
decrease in haemoglobin and meeting laboratory-
deﬁned anaemia criteria during 6 months
We have further evaluated the decrease in haemoglobin
in both trials using a singular absolute cut-off value at
6 months of £11.5 g⁄dL, the laboratory-deﬁned lower
limit of normal (LLN) for haemoglobin values in the
CONDOR trial (but not the CLASS trial – please refer to
text below). Among the celecoxib patients who had a
decrease in haemoglobin ‡2g⁄dL, 21.4% (12⁄56) of
patients in CLASS and 18.2% (8⁄44) of patients in CON-
DOR had a ﬁnal haemoglobin value £11.5 g⁄dL. In con-
trast, in the diclofenac arms 16.0% (8⁄50) of patients in
CLASS and 51.2% (63⁄123) of patients in CONDOR
who had a decrease in haemoglobin ‡2g⁄dL had a ﬁnal
haemoglobin value £11.5 g⁄dL.
As the LLN for haemoglobin values were different for
men (<12.7 g⁄dL for men aged 12–59 years and
<12.5 g⁄dL for men aged 60–150 years) and women
(<11.6 g⁄dL for women aged 12–59 years and <11.5 g⁄dL
for women aged 60–150 years) in the CLASS trial, we
further calculated decreases in haemoglobin ‡2g⁄dL in
men and women separately. As such, in the CLASS trial
the odds ratio for patients having decreases in haemoglo-
bin ‡2g⁄dL was 1.63 for women (95% CI, 0.98–2.72)
and 2.06 men (95% CI, 1.14–3.74) (Table S3).
Table 2 | Baseline demograph-
ics in non-aspirin users in the
CLASS and CONDOR trials Characteristics
CLASS CONDOR
Celecoxib
(n = 3105)
Diclofenac
(n = 1551)
Celecoxib
(n = 2238)
Diclofenac SR
(n = 2246)
Women, % 71.2 70.0 82.6 81.1
Diagnosis, %
OA 68.4 69.6 84.1 84.2
RA 26.4 25.3 15.9 15.8
OA & RA 5.2 5.1 – –
Mean age, years (s.d.) 59.5 (11.7) 59.0 (12.0) 65.2 (7.8) 65.3 (7.6)
White, % 87.9 88.5 55.3 54.0
Previous history of GD ulcer, % 7.8 8.4 17.7 17.8
H. pylori infection,% 38.2 37.3 – –
Haemoglobin (g⁄dL) 13.6 (1.3) 13.6 (1.3) 13.6 (1.1) 13.6 (1.1)
GD, gastroduodenal; OA, osteoarthritis; RA, rheumatoid arthritis.
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Our study demonstrates that continuous 6-month expo-
sure to NSAIDs is associated with a clinically meaningful
decrease in haemoglobin; a meaningful decline in
haemoglobin was observed in all of the treatment arms
in both trials in the absence of aspirin use. However,
despite differences in the study design and population of
the two trials, these results were reproducible for both.
Furthermore, the studies demonstrated that patients trea-
ted with diclofenac were two- to threefold more likely to
reach the meaningful end point than patients treated
with the COX-2 selective NSAID celecoxib. We believe
that this information focused on the development of pro-
gressive haemoglobin decreases with the chronic use of
NSAIDs, independent of acute bleeding events, and high-
lights the relatively understudied clinical issue of long-
term chronic occult blood loss.
A decrease in haemoglobin of ‡2g⁄dL has previously
been considered as a clinically meaningful end point
18 in
Figure 3 | Kaplan–Meier sum-
maries in non-aspirin patients
with haemoglobin decreases
(‡2g⁄dL) in the (a) CLASS
and (b) CONDOR trials.
*Estimated proportion at
month 6.
Table 3 | Aspirin users in CLASS (crude rates over
6 months)
No decrease in
haemoglobin, n (%)
With a decrease in
haemoglobin, n (%)
Celecoxib
N = 872
841 (96.44) 31 (3.56)
Diclofenac
N = 438
412 (94.06) 26 (5.94)
OR = 1.71 (1.00–2.92)
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ably, this assumes a decrease in haemoglobin of ‡2g⁄dL
is reﬂective of overt or occult blood loss and represents a
level of decline that is clinically meaningful and could
prompt physicians to intervene with new clinical deci-
sions and⁄or interventions. While we believe that such
decreases in haemoglobin can impact clinical care,
adverse outcomes potentially attributed to declines in
haemoglobin are not captured in either study.
Based on these considerations, this practical end point
has previously been utilised as an important outcome in
a number of large GI outcome trials evaluating
NSAID-associated toxicity such as VIGOR (Vioxx Gastro-
intestinal Outcomes Research),
4 CLASS,
8 TARGET
(Therapeutic Arthritis Research and Gastrointestinal
Event Trial)
6 and MEDAL (Multinational Etoricoxib and
Diclofenac Arthritis Long-term).
5 Moreover, the direct
clinical relevance of this end point and, notably the
development of anaemia, are further supported in the lit-
erature as being associated with a signiﬁcant increased
risk of recurrent falls, hospitalisations and mortality, par-
ticularly in older adults.
19–22 In addition, anaemia or
occult blood loss may result in diminished physical per-
formance and a lesser quality of life.
23–25 Low haemoglo-
bin levels are now recognised as an important issue that
affects a number of clinical patient outcomes – in partic-
ular, the clinical impact of anaemia in the elderly popu-
lation has been clearly documented.
19–22
Both the CLASS (conducted from 1998–2000) and
CONDOR (conducted from 2005–2009) trials were
designed to assess NSAID-related damage in the GI
tract in patients with undeﬁned or increased GI risk,
respectively. However, there were a number of differ-
ences between the two trials that potentially affected the
ﬁndings (Table 1). One of the key differences was that
in CLASS patients were randomised to diclofenac alone
whereas, in CONDOR patients in the comparator group
were randomised to diclofenac SR plus a PPI (omepra-
zole 20 mg o.d.). While the addition of a PPI in the
CONDOR trial would be expected to reduce the impact
of diclofenac on the upper GI tract with little or no
effect in the lower GI tract, the rate of deﬁned upper
GI events was still higher in the diclofenac plus PPI
arm than in the celecoxib arm.
16 However, overall the
rate of upper GI events was relatively small and thus,
we believe the majority of the meaningful blood loss
end points were not driven by any small differences in
upper GI outcomes but instead are likely to reﬂect small
bowel occult blood loss over time with continuous
NSAID exposure. Presumably this differential rate might
be reﬂected by the differences in injury patterns in the
small bowel following use of nonselective and COX-2
selective NSAIDs.
12, 13, 26
In the development of this post hoc analysis, differ-
ences in the design of the two clinical trials excluded the
possibility for a pooled analysis. Patients in the CLASS
trial were on average younger than those in the CON-
DOR trial [mean age 59.1 years (s.d. 6.9) vs. 66.4 years
(s.d. 6.9), respectively], reﬂecting an increased level of
GI risk for patients in the CONDOR trial. There were
also differences in the dosing of medications between the
two trials; in the CLASS trial a higher dose of celecoxib
400 mg b.d. was used compared with celecoxib 200 mg
b.d. in the CONDOR trial. In addition, as this was a
non-US trial and diclofenac SR is one of the most popu-
lar NSAIDs used outside the United States, this formula-
tion was used in the CONDOR trial. However, it is
theoretically possible that the diclofenac SR formulation
used in the CONDOR trial may have been associated
with a differing degree or location of intestinal injury as
compared to the diclofenac formulation in the CLASS
trial, although there is a lack of any head-to-head com-
parisons between the two formulations in the literature
regarding small bowel injury.
Furthermore, in the CLASS trial both H. pylori
positive and negative patients were included in the analy-
sis, whereas in CONDOR patients who tested positive
for H. pylori were excluded from the study (unless they
were speciﬁcally treated for their infection and subse-
quently tested negative). As seen in Figure 1, over the
ﬁrst 6 months of the CLASS and CONDOR trials the
frequency of scheduled laboratory evaluations differed.
While CLASS subjects had three evaluations after base-
line, in the CONDOR trial there were four post-baseline
evaluations scheduled. As such the frequency of labora-
tory evaluations might have inﬂuenced the rate of events
observed in the CONDOR trial as compared with CLASS
(Figure 3a,b).
We made several speculations in the analysis of these
data. While we believe the reported haemoglobin changes
are due to GI blood loss, we have no data regarding
occult blood loss to prove this is true. Moreover, there
were also patients embedded in the population who had
other reasons for the decrease in haemoglobin seen over
time. Of those cases reaching the predeﬁned ‡2g⁄dL
decrease in haemoglobin component of the primary end
point in the CONDOR population, 32% of patients were
adjudicated as having a non-GI aetiology due to other
causes (e.g. ﬂare of their underlying rheumatological
disorder).
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uate changes in haemoglobin, as suggested by the US
Food and Drug Administration (FDA) and used by others,
we did not directly evaluate medical outcomes associated
with the development of this meaningful drop in haemo-
globin. These end points, such as recurrent falls, hospitali-
sations and mortality, would not be expected to occur to a
signiﬁcant degree over the limited time frame of this study
and given the limited number of patients.
Based on our 6-month data as shown above, and in Fig-
ure 3a,b, there is a discrepancy between the trials in the rel-
ative number of patients achieving the laboratory-deﬁned
(£11.5 g⁄dL) anaemia end point. In CONDOR a signiﬁ-
cantly greater number of patients in the diclofenac group
had a ‡2g⁄dL decrease in haemoglobin and a haemoglobin
value £11.5 g⁄dL during 6 months. However, in CLASS
this difference was not apparent. Interestingly the differ-
ence between the two trials is not readily explained by a dif-
ference in the mean haemoglobin values for the two
populations at baseline. In the CLASS trial, the mean hae-
moglobin values at the onset of the study were 13.6 (s.d.
1.3) in the celecoxib and diclofenac treatment arms, respec-
tively. In the CONDOR trial the mean haemoglobin values
at baseline were 13.6 (s.d. 1.1) for both treatment arms
(Table 2). Given the small number of patients achieving
haemoglobin values £11.5 g⁄dL in the CLASS trial it would
be imprudent to draw any immediate conclusions regard-
ing the developmentof anaemia in this trial.
Despite its limitations we believe this study provides
important clinical ﬁndings. Decreases in haemoglobin are
clinically meaningful in that they drive medical evalua-
tions and increased cost of care – the use of the absolute
cut-off of ‡2g⁄dL has been advocated by the FDA
18 and
supported by the European Medicines Agency (EMA),
among other researchers.
In these two large-scale, randomised and independent
outcome trials clinically meaningful decreases in haemo-
globin ‡2g⁄dL occurred in a similar fashion over time
despite differences in trial design. Among non-aspirin
using populations, a signiﬁcantly greater number of
patients treated with diclofenac had reductions in
haemoglobin as compared with patients treated with
celecoxib over 6 months. Interestingly, the difference
between these two arms in CLASS, in both the aspirin
and non-aspirin using population, is consistent with
numerically similar odds ratios.
We believe that the reproducibility of these ﬁndings
over 6 months conﬁrms their clinical importance in this
age-relevant population with arthritis and that these data
will provide the foundation for future research regarding
the effects of anti-inﬂammatory agents throughout the
entire GI tract.
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